Par Pharma acquires rights to thin-film drug technology
-
- June
- 17
Strativa Pharmaceuticals, the branded drug unit of Par Pharmaceuticals Cos., which employs some 440 workers in Rockland County, has acquired the U.S. rights to a thin-film formulation of an anti-emetic drug, known as Ondansetron, for use by cancer patients.
Anti-emetics are drugs the prevent nausea and vomiting, frequent side effects of radiation and chemotherapy. The drug, should it make it to market, would resemble breath strips, postage stamp-sized films that dissolve in the mouth.
Terms of the deal with Warren, N.J.-based MonoSol Rx, the developer of the thin-film technology, weren’t disclosed, but milestone payments to MonoSol could reach $23.5 million, the companies said.
U.S. sales of anti-emetics reached more than $1.6 billion last year, Par said.
Par, based in Woodcliff Lake, N.J., previously secured rights to Ondansetron for use as an oral spray, currently in development.
MonoSol said it is moving quickly to trials of the thin-film version with the hope of filing a new drug application with U.S. regulators within a year.
This entry was posted
on Tuesday, June 17th, 2008 at 4:41 pm by David Schepp.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
| 
Email
